Epizyme Priced, Nasdaq: EPZM
Biotech developing therapeutics for patients with genetically defined cancers.
Industry: Health Care
First Day Return: +53.3%
EPZM
Biotech developing therapeutics for patients with genetically defined cancers.
| IPO Data | |
|---|---|
| IPO Date | 05/30/2013 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $77 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Cambridge, MA, United States |
| Founded | 2007 |
| Employees at IPO | 64 |
| Website www.epizyme.com | |
Epizyme (EPZM) Performance
